The New England journal of medicine 2025 Feb 06

Perioperative Durvalumab in Bladder Cancer.

Related Questions

Would you consider omitting adjuvant durvalumab in MIBC to limit overtreatment in patients who may not benefit or those who have achieved maximal benefit after neoadjuvant gem/cis/durva?

Medical Oncology · University of California Los Angeles, Los Angeles

The NIAGARA protocol included neoadjuvant durvalumab in combination cisplatin/gemcitabine, followed by adjuvant durvalumab regardless of the pathologic response at the time of surgery. Therefore, even those with pCR completed the year of adjuvant therapy. What is important to point out is that we do...